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Chapter 1: INTRODUCTION 
The small, yet highly conserved ubiquitin polypeptide can be found in all 
eukaryotes that have been studied thus far.  Protein ubiquitination is a post-
translational modification involved in many cellular processes including 
metabolic regulation and ATP-dependent protein degradation.  The latter is of 
great importance as it allows removal of damaged or abnormal proteins 
whose accumulation could be detrimental to the cell.   
The ubiquitin-proteasome system is responsible for the degradation of 
many cellular proteins.  This non-lysosomal pathway consists of proteins 
involving a wide range of functions that act cooperatively on proteins that 
have been tagged by ubiquitin degradation.  Ubiquitinating enzymes, E1 
(ubiquitin activation), E2 (ubiquitin conjugation), and E3 (ubiquitin ligation), 
are responsible for the covalent attachment of ubiquitin to targeted cellular 
substrates in preparation for degradation via the 26S proteosomal pathway 
[1].  Comparably, deubiquitinating enzymes function to remove ubiquitin from 
these protein substrates so the ubiquitin may be regenerated and used for 
other condemned proteins [2, 3].  Deubiquitinating enzymes are grouped into 
two families: ubiquitin proteases (UBPs) and ubiquitin carboxy-terminal 
hydrolases (UCHs).  The work presented here attempts to obtain sequence 
information of one UCH isozyme: UCH-L1. 
Highly conserved and homologous within eukaryotes, the mammalian 
UCH family consists of three isozymes, L1, L2, and L3.  Isozymes L1 and L3 
have been found in human cells.  These enzymes are cytoplasmic thiol 
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proteases that selectively hydrolyze the peptide bond at the carboxy-terminal 
glycine of ubiquitin molecules [4, 5].  UCH-L3 is found in the heart, lung and 
brain, while UCH-L1 is not as widely distributed.  Alternatively labeled neuron 
cytoplasmic protein 9.5, or PGP9.5, UCH-L1 is localized in neuronal 
cytoplasm, comprising 1-2% of total soluble brain proteins, making it one of 
the most abundant brain proteins [6, 7].  It is also found in the testis [8-11].    
In vivo, UCH-L1 is associated with monoubiquitin and elevates the level of 
monoubiquitin in neuron [5]. There are also reports of UCH-L1 acting as an 
ubiquitin ligase under dimerization conditions [12, 13].  According to the gene 
sequence, UCH-L1 consists of 223 amino acids, and gel electrophoresis 
measurements show the protein’s migration corresponding to approximately 
24.8 kDa.   
Elucidation of the exon sequences of the gene encoding UCH-L1 was 
completed followed by publication of the intron sequences flanking those 
exons [14].  It was found that there are nine coding exons spanning a 10 kb 
range.  The gene has been mapped to chromosome locus 4p14 by PCR 
analysis [15].  Mutagenesis and kinetic experiments identify cysteine 90 and 
histidine 161 as the active site nucleophile and general base for catalysis [16, 
17]. The same experiments also found that UCH-L1 binds the intact ubiuqitin 
C-terminus, but not the amino terminus. 
UCH-L1 is of growing interest in the proteomics research community 
because of its implications in various neurodegenerative diseases including 
Parkinson’s disease (PD) and Alzheimer’s disease (AD) [12, 13, 18-31].  The 
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protein is found in Lewy bodies and neurofibrillary tangles, which are 
pathogenic markers for PD and AD, respectively.  The degradation of some 
protein aggregates by the ubiquitin proteasome system (UPS) is imperative 
for mental health.  As a deubiquitinating enzyme, UCH L1 possesses an 
enzymatic activity that contributes to the stability of the UPS. UCH-L1 gene 
mutants have been linked to Parkinson’s disease via an isoleucine-
methionine mutation at residue 93.  Research has shown that this I93M 
mutation decreases the catalytic activity of UCH-L1 in vitro. This in turn may 
lead to impairment of the UPS causing neuronal polyubiquitinated inclusions 
to form in excess. Without access to the degradation pathway, they are not 
subjected to normal processing, leading to the loss of functioning neurons 
and diminished mental health, as is the case for certain types of Parkinsonism 
and Alzheimer’s disease.  In contrast, an S18Y polymorphism has been 
linked to decreased susceptibility to PD in certain populations [19, 23, 32-35].  
Researchers have also reported high UCH-L1 expression in different 
types of cancers. Hanash et. al [36] use a proteomic approach to detect UCH-
L1 (referred to as PGP9.5 in their report) in small cell carcinoma, 
adenocarcinoma, squamous cell carcinoma, and neuroendocrine 
differentiated adernocarcinoma and propose it is a biomarker.  Other studies 
suggest that UCH-L1 may be associated with lung cancers [37-41]. Hathout 
et al. [42] have also reported an increased expression of UCH-L1 protein in 
drug-resistant and metastatic cancer cell lines.  These associations of UCH-
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L1 with two very different diseases suggest that mutation, processing, and/or 
post-translational modifications may be important in directing its functions.  
 
Post-translational Modifications
Protein modifications are widespread in protein expression. Some 
derivitizations arise as artifacts of sample preparation, such as oxidation; 
other derivitizations may be deliberately introduced, such as cysteine 
modifications to deter disulfide bridging.  However, a majority of modifications 
occur after the translation process- after the ribosome has synthesized the 
protein.  These modifications include enzymatic cleavage of a precursor 
protein or the attachment of biochemical functional groups to individual amino 
acid residues.  Proteolytic cleavage can activate inactive proproteins, such as 
the activation of trypsin from trypsinogen. 
Common covalent post-translational modifications that involve the 
attachment of functional groups include phosphorylation, glycosylation, 
acetylation, and methylation, among many others.   
Phosphorylations, the addition of a phosphate group, are found on 
serine, tyrosine, and threonine residues.  Phosphorylation is a reversible 
modification that is catalyzed by protein kinases, and removed by protein 
phosphatases.  Protein phosphorylation has been found to be an activating 
switch for many cellular processes including signaling and cell growth.  One 
example of great physiological relevance is the release of glucose, the major 
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source of energy in the body: glycogen phosphorylase is activated by 
phosphorylation to produce glucose from glycogen molecules.  
Glycosylation, another dominant post-translational modification, is the 
attachment of saccharide groups to proteins.  Glycosylations are found on an 
abundance of eukaryotic proteins.  N-linked glycosylation is an attachment of 
oligosaccharide chains onto asparagine residues in a tripeptide sequence of 
Asn-X-Ser or Asn-X-Thr, where X is any amino acid except proline.  O-linked 
glycosylation is found on the hydroxyl groups of serine and threonine 
resiudes.  Glycosylation has a role in many different functions including 
protein folding and glycoprotein secretion.   
Currently, there is evidence that UCH-L1 may be post-translationally 
glycoslyated.  Cole and Hart [43] have reported N-acetylglucosamine (O-
GlcNac) modifications in cytosolic fractions of proteins in nerve terminals.  
They use PNGase F-resistant galactosyltransferase labeling to identify O-
GlcNAc modifications in synaptosome proteins.  UCH-L1 was one of three 
proteins they identified as modified.   
 
Mass Spectrometry
Mass spectrometry (MS) is a powerful and useful tool for analyzing all 
types of biomolecules over a vast range of masses.  The extreme versatility of 
mass spectrometry makes it applicable to a broad range of samples including 
microorganisms, drugs, and proteins.  Mass spectrometry provides the mass 
of a sample analyte by determining the mass-to-charge ratio (m/z) of its ionic 
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species.  Samples subjected to MS must be vaporized and charged. A mass 
spectrometer consists of four basic components: sample inlet, ionization 
source, mass analyzer, and the detector.  The sample inlet is the area in 
which the sample is introduced to the instrument.  The ionization source 
generates analyte ions by inducing either the loss or gain of charge.  Ions are 
then electrostatically directed to the mass analyzer where they are separated 
according to the m/z ratio.  The ion detector then converts the ion energy into 
electrical signals.  The resulting mass spectrum displays peaks corresponding 
to the m/z ratio of all charged species in the analyte.  The spectrum plots the 
m/z on the x-axis against the relative intensity of each peak on the y-axis.  
(The relative intensity shows the abundance of an individual m/z in relation to 
the most intense peak in that particular spectrum). 
There are many ionization techniques for mass spectrometry.  Two 
very common sources include matrix–assisted laser desorption ionization 
(MALDI) and electrospray ionization (ESI), both of which have helped to 
broaden the limits of mass spectrometric applications, especially to include 
proteins and peptides.   
MALDI incorporates the use of a multi-functional chromophoric organic 
matrix in excess.  As a chromophore, it absorbs the ultraviolet radiation from 
the laser beam; and as an acid, it provides protons for ionization of the 
analyte.  The matrix is applied to the sample and allowed to dry, thus co-
crystallizing with the analyte.  A laser beam eradicates the crystals, causing 
the matrix phase to readily shift from solid to compressed gas, carrying with it 
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the analyte molecules.  The analyte molecules are ionized in this process and 
are directed toward the mass analyzer to be separated. 
Electrospray ionization also occurs through a series of processes that 
produce gaseous, ionized molecules directly from the liquid sample.  First, a 
voltage of approximately 2 kV is applied to the ES capillary tip, producing 
charged droplets.  Second, as heat is applied to the droplets, the solvent 
evaporates, causing an increase in the charge density.  As coulombic 
repulsions grow stronger, surface tension forces grow weaker, and the 
sample ions are released and fly through to the vacuum of the mass analyzer. 
Peptide mass mapping is a useful MS technique for protein 
identification.  For this, the protein is subjected to proteolytic digestion to 
produce peptides that can be analyzed more readily than the more 
hydrophobic intact protein.  Choice of digestion enzyme is fundamental to 
producing useful peptides. Trypsin is one of the most common digestion 
enzymes, and is used in the present study.  It cleaves peptide bonds on the 
C-terminal side of lysine and arginine residues, at an optimal pH between 7.5 
and 9.0.  Depending on the desired properties of the resulting peptides, there 
are many other proteases which can be used.  The other enzyme used for 
this work is endoproteinase Glu-C, which cleaves peptide bonds on the C-
terminal side of glutamic acid at pH of 7.8. 
The resulting peptide mixture can be analyzed by mass spectrometry.  
Analyzing proteins at the peptide level provides more detailed look at the 
protein under study, and allows localization of modifications. 
8
Objective 
The objective of this thesis is to develop methods to characterize the UCH-L1 
protein structure and develop an approach to identify post-translational 
modifications by peptide mass fingerprint through mass spectrometry. 
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Chapter 2: EXPERIMENTAL 
Gel Electrophoresis 
Human recombinant UCH-L1 [1µg/µl], expressed in E. coli, was 
purchased from Boston Biochem (Cambridge, MA).  DL-Dithiothreitol (DTT; 
Sigma, St. Louis, MO) was always prepared fresh immediately before its use.  
β-mercaptoethanol (Sigma), a reducing agent, was added to Laemmli sample 
buffer (Bio Rad, Hercules, CA) immediately before use.  Tris-HCl 
polyacrylamide Criterion Gels with 10-20% linear gradient (Bio-Rad) were 
used for electrophoresis.  Stock solution of 5X running buffer for 
electrophoresis consisted of 25mM Tris (Sigma), 192 mM glycine (Sigma), 
and 0.1% sodium dodecyl sulfate (SDS) (Sigma).  Low-range pre-stained 
SDS-PAGE standards were purchased from Bio Rad.  Fixing solution 
consisted of 35% methanol (J.T. Baker, Phillipsburg, NJ), 15% glacial acetic 
acid (J.T. Baker), and 50% deionized water (Millipore, Billerica, MA).  Bio-
SafeTM Coomasie was obtained from Bio Rad.  Densitometry was performed 
on the GS-800 calibrated densitometer (Bio Rad). 
Two microliters of human recombinant UCH-L1 was added to a 
microcentrifuge tube.  Two microliters 10 mM DTT was added.  The sample 
was incubated for 15-20 minutes at room temperature.  To prepare the 
sample buffer, 12.5 µl of β-mercaptoethanol were added to 237.5 µl Laemmli 
sample buffer and mixed well by vortex.  Eight microliters of sample buffer 
were then added to the protein sample and mixed by pipette.  The sample 
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was placed in a boiling water bath for five minutes.  The Criterion gel was 
placed in the cell and filled with approximately 400 µl 1X running buffer. A 
small syringe was filled with running buffer and used to flush any residual 
SDS from each well.  After cooling to room temperature, 10 µl of sample and 
the molecular weight markers were each loaded onto separate lanes on the 
gel.  Running buffer was added to the sample chamber.  The gel was run at 
200 volts for approximately one hour.  After electrophoresis, the gel was 
incubated with fixing solution for 45 minutes, followed by deionized water for 
15 minutes, and finally stained in Coomasie blue overnight.  The gel was 
destained in deionized water for 5 hours.  Calibrated densitometry was used 
to capture an image of the gel. 
 
In-Solution Digestion
Immobilized L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK) 
trypsin and HandeeTM microcentrifuge tubes were purchased from Pierce 
(Rockford, IL).  Endoproteinase Glu-C was purchased from Sigma.  The 
digestion buffers for the trypsin and Glu-C digestions consisted of 0.1 M 
NH4HCO3, pH 8.0 and 7.8, respectively.  The pH was adjusted with 6M 
sodium hydroxide (NaOH) (Fisher) as needed.   
Five microliters of immobilized TPCK trypsin was added to a 
microcentrifuge tube and washed by adding 10 µl of digestion buffer.  The 
tube was centrifuged for 15 sec at 4.0 rpm.  The supernatant was removed by 
pipette and the wash was repeated two times.  The trypsin beads were 
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resuspended in 5 µl of digestion buffer.  Five microliters of human 
recombinant UCH-L1 was added to a microcentrifuge tube.  Five microliters of 
0.1 M DTT was added to the protein and incubated for 15 minutes.  Three 
microliters of digestion buffer was added to the reduced protein sample.  The 
protein sample was transferred to the tube containing the trypsin and mixed 
by pipetting.  The sample was incubated overnight at 37ºC.  Following 
overnight enzymatic digestion, the supernatant was recovered from the 
trypsin and transferred to a new centrifuge tube.  The tryptic peptides were 
concentrated in the speed vac and dissolved in 0.1% TFA.  The peptide 
solution was subjected to desalting with Zip Tip C18 as already described.  
The peptides were dried completely in the speed vac and reconstituted in 
electrospray buffer (methanol, water, glacial acetic acid, 49:49:2, v/v/v). 
The endoproteinase Glu-C digestion was performed according to the 
manufacturer’s instructions.  The lyophilized Glu-C product was reconstituted 
in 250 µl of deionized water, resulting in a final concentration of 0.1 µg/µl.  A 5 
µl aliquot of human recombinant UCH-L1 was dried down in the speed vac 
and reconstituted in 5 µl of digestion buffer.  To achieve an enzyme-to-
substrate ratio of 1:20, 2.5 µl of Glu-C solution was added to the protein 
sample.  The sample was incubated for 14 hours at 37ºC.  The Glu-C 
peptides were dried down in the speed vac and reconstituted in 5 µl 0.1% 
TFA.  The peptides were desalted with a Zip Tip C18 column as described 




Mass Spectrometry and Bioinformatics
The intact protein and proteolytic peptides were analyzed by mass 
spectrometry.  The intact protein was first analyzed by matrix-assisted laser 
desorption ionization time-of-flight mass spectrometry (MALDI-ToF MS) on an 
AXIMA-CFR instrument (Kratos Analytical, Chestnut Ridge, NY) equipped 
with pulsed extraction and a nitrogen laser operating at 337 nm.  The matrix 
was saturated 3,5-dimethoxy-4-hydroxycinnamic acid in 70% ACN / 0.1% 
TFA. A sterile petri dish was filled with fifty microliters of deionized water.  A 
dialysis membrane (Millipore) was placed on top of the water.  Four 
microliters of human, recombinant UCH-L1 was placed directly on the surface 
of the membrane and dialyzed for 30 minutes for desalting. One microliter of 
protein sample was placed between one-microliter layers of matrix on the 
MALDI plate. For MALDI-MS, a three-point calibration was first performed. 
The calibrants and their corresponding weights are as follows: cytochrome c, 
12,361.96 Da; apomyoglobin, 16,952.27 Da,  aldolase, 39,212.28 Da.  The 
mass range scanned was from 1,000-70,000 Da, in linear mode. 
The intact protein and peptides from the in-solution digests were 
analyzed by electrospray ionization mass spectrometry (ESI-MS) on the API 
QSTAR Pulsar Qq-TOF (Applied Biosystems, Foster City, CA) utilizing a 
nanospray source (Protana A/s, Odense, Denmark).  All scans were 
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performed with the following parameters: positive ion mode; ion spray voltage 
= 0.9 kV; curtain gas = 25 L/min; resolution = 2400 CEM. 
 For peptide analysis with ESI-MS, a two-point calibration was 
performed with Angiotensin II at m/z 1046.5 and 523.0. Two microliters of the 
peptide mixture were introduced into the ionization source via 
nanoelctrospray disposable needles (Proxeon Biosystems, Denmark).  The 
TOF-MS scan was measured first to identify the m/z values of the peptide 
molecular ions.  This precursor scan range was set to examine m/z 350-1500 
and the instrument generated spectra accordingly.  Collision induced 
dissociation was used for MS/MS analysis.  Here, multiply charged molecular 
ions of interest from the MS spectra were isolated in Q1, the mass filter 
quadrupole cell, and solely passed into Q2, the collision cell.  In these product 
ion scans, fragmentation was induced by nitrogen gas transmitted into Q2.  
During acquisition, the collision energy was adjusted as necessary to produce 
fragments, typically b- and y-ions, depending on the charge retention site 
following fragmentation. 
For analysis of the intact protein with, 2 microliters of sample were 
dialyzed against water and subjected to ESI-MS.  The scan range was m/z 
600-4000. 
 Theoretical peptides were generated using GPMAW software 
(Lighthouse Data, Denmark).  This computer program has the ability to 
provide masses of the singly and multiply charged ions from various 
proteolytic digests.  Furthermore, it provides the masses of the fragment a-, b-
14 
 
, x-, and y-ions from MS/MS analysis.  The SwissProt accession number for 
human UCH-L1, P09936, was used for GPMAW.   
15 
 
Chapter 3: RESULTS 
The molecular weight of intact human, recombinant UCH-L1 was 
obtained on MALDI-MS and ESI-MS, as well as gel electrophoresis.  Figure 1 
shows the densitometry image of the SDS-PAGE experiment.  The intact 
protein migrates to a position at approximately 27 kDa, as seen by its position 
relative to the adjacent molecular weight standards. 
 










Figure 2 shows the MALDI-MS spectrum of the intact protein with high 
abundance peaks at m/z = 8,284; 12,420; and 24,830 Da, representing the 
triply, doubly and singly charged ions, respectively.  The lower intensity peak 
m/z 49,617 Da is due to an artifactual dimerized cluster of the protein. 
 


















The ESI-MS spectrum shows a characteristic charge distribution of the 
molecular ions of the intact protein, as seen in Figure 3.  The charged species 
within this distribution range from M+34H+ to M+17H+, at m/z = 731.61 Da 
and 1,462.35 Da, respectively.  Using the Bayesian Peptide Reconstruct 
feature on the Analyst 1.1 software, the molecular ions from the TOF-MS 
scan were deconvoluted to show the neutral species.  In Figure 4, the 
reconstructed chromatogram shows a single peak at m/z 24,840.00.  No 
dimer was observed.   
The ESI-TOF-MS deconvoluted spectra from the proteolytic digests 
are shown in Figures 5 and 6.    The monoisotopic masses from each peak 
are listed, along with the theoretical peptide masses and the differences 
between these values, in Tables 1 and 2. 
For further analysis and verification, a select group of ions from the 
TOF-MS scan were fragmented by MS/MS for sequence verification.  The 
product ion scans from selected TOF-MS ions are shown in Figure 7 and 8.  
The b- and y-ions of the fragment sequences are displayed in the spectrum 
window. 
The sequence coverage is a ratio of the number of amino acids in the 
identified peptides to the total number of amino acids in the sequence, 
defined as follows: 
 
% Sequence coverage =  # of amino acids in the identified proteins X100% 




When treated with immobilized TPCK trypsin alone, the sequence coverage 
was 58% of the protein. The Glu-C digest achieved 48% sequence coverage.   
 
Figure 3: Electrospray ionization mass spectrum of intact UCH-L1 



























Figure 4: Deconvoluted mass spectrum from Fig. 3 












Figure 5: Deconvoluted electrospray ionization mass spectrum of trypsin 
digest 
 






















Figure 6: Deconvoluted electrospray ionization mass spectrum of 
endoproteinase Glu-C digest 
























∆ M Amino 
Acid # 
Peptide Sequence 
4761.4867*   20-63 LGVAGQWRFVDVLGLEEE
SLGSVPAPACALLLLFPLTA
QHENFR 
4342.1270*   158-195 VNFHFILFNNVDGHLYELD
GRMPFPVNHGASSEDTLLK
4022.1101*   28-64 FVDVLGLEEESLGSVPAPA
CALLLLFPLTAQHENFRK 
3894.0152   28-63 FVDVLGLEEESLGSVPAPA
CALLLLFPLTAQHENFR 
3297.6538*   84-115 QTIGNSCGTIGLIHAVANNQ
DKLGFEDGSVLK 
2975.4566*   154-178 VDDKVNFHFILFNNVDGHL
YELDGR 
2920.4450*   79-105 VYFMKQTIGNSCGTIGLIHA
VANNQDK 
2518.2393   158-178 VNFHFILFNNVDGHLYELD
GR 
2415.0696*   132-153 CFEKNEAIQAAHDAVAQEG
QCR 
2366.0795*   136-157 NEAIQAAHDAVAQEGQCR
VDDK 
2270.1949* 2269.86 0.33 1-19 MQLKPMEINPEMLNKVLSR 
2252.1093   84-105 QTIGNSCGTIGLIHAVANNQ
DK 
2227.0943*   179-199 MPFPVNHGASSEDTLLKDA
AK 
2026.0259*   106-123 LGFEDGSVLKQFLSETEK 
1908.8622 1908.88 0.03 136-153 NEAIQAAHDAVAQEGQCR 
1841.8982 1840.85 1.05 179-195 MPFPVNHGASSEDTLLK 
1814.9093 1813.93 0.73 1-15 MQLKPMEINPEMLNK 
1695.7774* 1696.97 1.19 116-129 QFLSETEKMSPEDR 
1534.7688*   208-221 EQGEVRFSAVALCK 
1483.7882* 1482.96 0.83 66-78 QIEELKGQEVSPK 
1411.7170* 1412.91 1.19 72-83 GQEVSPKVYFMK 
1378.6477* 1377.91 0.74 203-213 EFTEREQGEVR 
1340.7677*   16-27 VLSRLGVAGQWR 
1063.5550 1062.97 0.59 106-115 LGFEDGSVLK 
1037.4838*   200-207 VCREFTER 
(*) indicates missed cleavage 
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∆ M Amino 
Acid # 
Peptide Sequence 
980.4815 979.93 0.55 116-123 QFLSETEK 
978.5083*   214-223 FSAVALCKAA 
932.4386*   124-131 MSPEDFRAK 
886.5124*   65-71 KQIEELK 
885.4821 884.99 0.49 20-27 LGVAGQWR 
836.4340 836.98 0.55 214-221 FSAVALCK 
760.3776*   196-202 DAAKVCR 
758.4174 758.00 0.42 66-71 QIEELK 
743.3814 742.97 0.41 72-78 GQEVSPK 
733.3065 732.91 0.40 124-129 MSPEDR 
723.3500*   130-135 AKCFEK 
716.3453   208-213 EQGEVR 
686.3462 685.96 0.39 79-83 VYFMK 
680.3130   203-207 EFTER 
524.2179   132-135 CFEK 
475.2278   154-157 VDDK 
473.2962 473.04 0.26 16-19 VLSR 
403.2067 403.98 0.77 196-199 DAAK 
375.1814 374.02 0.16 200-202 VCR 
274.2005*   64-65 KK 
217.1426   130-131 AK 
160.0848   222-223 AA 
146.1055   64-64 K 
146.1055   64-64 K 
(*) indicates missed cleavage 
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5285.8223*   12-60 MLNKVLSRLGVAGQWRFV
DVLGLEEESLGSVPAPACA
LLLLFPLTAQHE 
4981.5232*   75-120 VSPKVYFMKQTIGNSCGTI
GLIHAVANNQDKLGFEDGS
VLKQFLSE 
4673.1890*   150-190 GQCRVDDKVNFHFILFNNV
DGHLYELDGRMPFPVNHG
ASSE 
4333.2113*   70-109 LKGQEVSPKVYFMKQTIGN
SCGTIGLIHAVANNQDKLGF
E
4181.9892*   138-174 AIQAAHDAVAQEGQCRVD
DKVNFHFILFNNVDGHLYE 
3777.9097   75-109 VSPKVYFMKQTIGNSCGTI
GLIHAVANNQDKLGFE 
3518.8834*   38-69 SLGSVPAPACALLLLFPLTA
QHENFRKKQIEE 
3410.8020*   8-37 INPEMLNKVLSRLGVAGQW
RFVDVLGLEEE 
3154.5414*   175-203 LDGRMPFPVNHGASSEDT
LLKDAAKVCRE 
2977.4055   150-174 GQCRVDDKVNFHFILFNNV
DGHLYE 
2957.5797   12-37 MLNKVLSRLGVAGQWRFV
DVLGLEEE 
2346.2532   38-60 SLGSVPAPACALLLLFPLTA
QHE 
1836.9166*   191-206 DTLLKDAAKVCREFTE 
1745.9424*   61-74 NFRKKQIEELKGQE 
1712.7941 1712.66 0.13 175-190 LDGRMPFPVNHGASSE 
1593.7747*   135-149 KNEAIQAAHDAVAQE 
1547.8004* 1548.51 0.71 209-223 QGEVRFSAVALCKAA 
1459.7579   191-203 DTLLKDAAKVCRE 
1451.7144* 1451.53 0.18 110-122 DGSVLKQFLSETE 
1438.6459* 1440.46 1.81 123-134 KMSPEDRAKCFE 
1328.6468* 1328.49 0.15 1-11 MQLKPMEINPE 
1237.5635*   128-137 DRAKCFEKNE 
(*) indicates missed cleavages 
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∆ Mass Amino 
Acid # 
Peptide Sequence 
1234.6778 1234.44 0.24 212-223 VRFSAVALCKAA 
1222.5942   138-149 AIQAAHDAVAQE 
1221.6241 1221.46 0.16 110-120 DGSVLKQFLSE 
1190.6408 1190.41 0.23 61-69 NFRKKQIEE 
875.4245 875.294 0.13 1-7 MQLKPME 
866.3831   128-134 DRAKCFE 
820.3637* 820.24 0.12 121-127 TEKMSPE 
680.3130* 681.1904 0.88 204-208 FTERE 
617.2769*   207-211 REQGE 
590.2734   123-127 KMSPE 
573.3122   70-74 LKGQE 
471.2329   8-11 INPE 
395.1692   204-206 FTE 
389.1910   135-137 KNE 
332.1332   209-211 QGE 
303.1543   207-208 RE 
248.1008   121-122 TE 
(*) indicates missed cleavage 
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Figure 7: Tandem mass spectrum of molecular ion 443.5. 
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Figure 8: Tandem mass spectrum of m/z 614.6. 
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The “additive sequence coverage” refers to combined sequence 
coverage from the two enzymes with different enzymatic specificity.  The 
additive sequence coverage of the recombinant UCH-L1 is 69%.  This slight 
increase is due to a small number of amino acids recovered in the Glu-C 
digest that are not identified in the tryptic digest.  The sequence coverages of 
both digests are displayed in Figures 9 and 10. 
 
MQLKPMEINP  EMLNKVLSRL  GVAGQWRFVD  VLGLEEESLG  SVPAPACALL  
LLFPLTAQHE  NFRKKQIEEL  KGQEVSPKVY  FMKQTIGNSC  GTIGLIHAVA  
NNQDKLGFED  GSVLKQFLSE  TEKMSPEDRA KCFEKNEAIQ    AAHDAVAQEG  
QCRVDDKVNF HFILFNNVDG  HLYELDGRMP  FPVNHGASSE  DTLLKDAAKV  
CREFTEREQG  EVRFSAVALC  KAA 
Figure 9: Sequence coverage of tryptic peptides. Red indicates matched 
peptides. 
 
MQLKPMEINP  EMLNKVLSRL  GVAGQWRFVD  VLGLEEESLG  SVPAPACALL  
LLFPLTAQHE  NFRKKQIEEL KGQEVSPKVY  FMKQTIGNSC  GTIGLIHAVA  
NNQDKLGFED GSVLKQFLSE  TEKMSPEDRA  KCFEKNEAIQ    AAHDAVAQEG  
QCRVDDKVNF HFILFNNVDG  HLYELDGRMP  FPVNHGASSE DTLLKDAAKV 
CREFTEREQG  EVRFSAVALC  KAA 





Chapter 4: DISCUSSION 
If the gene sequence for the protein under study is known, 
experimental data can be compared to the theoretical sequence.  The sample 
used in this study was UCH-L1 protein isolated from human cells and grown 
in an E. coli host.  Therefore, the recombinant sample is not expected to be 
modified much, because E. coli lacks the enzyme systems to carry out that 
processing.  However, using recombinant sample is an effective approach for 
primary analysis, as it provides a model for analysis, and a baseline for 
comparisons for future studies of cells containing abnormal UCH-L1 
expression.   
The molecular masses from the electrophoresis results vary from the 
mass spectrometry values. The SDS-PAGE image shows the monomeric 
protein’s migration at approximately 27 kDa, approximately 3,000 Da greater 
than both mass spectrometry values.  Mass spectrometry has greater mass 
accuracy than electrophoresis.  Other proteins are reported to behave in a 
similar manner in gel electrophoresis measurements [45].  To address the 
discrepant results between the two methods, it was important to analyze the 
proteolytic peptides of UCH-L1. 
Using mass spectrometry and peptide mass mapping techniques a 
total of 69% of the UCH-L1 human recombinant protein was recovered.  In 
the tryptic digest analysis, there are three peptides that were not recovered in 
the MS spectra (Table 3).  A common challenge in proteomics is retrieving 
peptides with higher masses (>2.5 kDa) after the digest.  Higher mass 
30 
 
peptides consist of longer amino acid sequences and tend to be more 
hydrophobic.  Increased hydrophobicity affects the solubility of these peptides 
making it difficult to resuspend them in solution after digestion and desalting.  
The first peptide listed in Table 3 contains two hydrophobic clusters, [FVDVL] 
and [ACALLLLF], which may have contributed to its insolubility and 
subsequent absence from the mass spectrum. 
 




3894.02 53 17 
VNFHFILFNNVDGHLY
ELDGR 
2518.24 48 29 
QTIGNSCGTIGLIHAV
ANNQDK
2252.11 41 14 
Table 3: Unmatched peptides from trypsin digest 
 
The Glu-C digest produced fewer peptides that corresponded to the 
values listed in the theoretical digest.  Many of these peptides included 
missed cleavage sites.  For many of the peptides with missed cleavages, 
there is a corresponding mass value of one of the two included peptides.  
This pattern is indicative of incomplete digestion and may be alleviated by 
longer incubation of the protein with the digestion enzyme or increased 
enzyme to protein concentration ratio.   
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It is important to note that the enzymatic activity of endoproteinase 
Glu-C is pH-dependent.  In addition to cleaving the C-terminal peptide bonds 
of glutamic acid residues at pH 7.8, this endoproteinase will also cleave C-
terminal peptide bonds of aspartic acid and glutamic acid residues at pH 4.  
There are two relatively intense peaks on the Glu-C digest spectrum, at m/z 
703.23 Da and 803.31 Da, which result from an aspartic acid residue 
cleavage.  Since these peptides are legitimate products of the Glu-C digest, 
they have been included in the sequence coverage calculations.   
In both enzymatic digestions, the observed mass values are within 1.8 
Da of the theoretical mass values, with an average ∆ mass of 0.5 ± 0.4 Da.  It 
can be concluded that the close agreements of these values indicate that 
there are no post-translational modifications present on these particular 
peptides of the recombinant protein.   
Another significant observation is the retention of the N-terminal 
methionine that serves as the translation initiation signal.  E. coli will 
commonly remove the N-terminal methionine in many proteins and/or 
formylate the N-terminus [46].  The N-terminal proteolytic peptides are seen in 
both digests with the methionine residue intact, and without variation in 
masses. 
High sequence coverage is not necessarily required for identification of 
unknown proteins. Many proteins can be identified by matching as few as 
three or four peptide masses [47].  However, when attempting to characterize 
any post-translational modifications, sequence coverage becomes significant.  
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Individual amino acids in the sequence may provide essential information to 
the overall structure or be a site for modification.   
One approach to increasing the sequence coverage of UCH-L1 would 
be through sequential proteolysis.  In the work presented here, two aliquots of 
recombinant UCH-L1 sample were digested separately, and their sequence 
coverages were compared.  With sequential proteolysis, one aliquot of UCH-
L1 can be digested with a primary protease; the resulting peptides would then 
be subjected to a second round of digestion with a different protease.  This 
technique would be beneficial for the high-mass peptides that are not being 
recovered in the initial digestion, such as the unmatched peptides mentioned 
above.  Maintaining the appropriate pH levels is imperative for this method, as 
most proteolytic enzymes only perform their enzymatic role in specific pH 
ranges. 
Liquid chromatography-MS may also be used to identify peptides from 
a proteolytic digest.  Liquid chromatography would provide peptidic separation 
prior to MS.  Adjustable gradients and flow rates allow analysis of peptides 
that pose challenges in one-dimensional mass spectrometry. Greater 
resolution of components in peptide mixtures is one advantage obtained 
when LC is coupled with MS.  Initial separation of a peptide mixture by LC-MS 
is sometimes warranted to reduce ionization suppression effects.  Other 
advantages of LC-MS include enhanced peak intensity, greater number of 
identifiable peaks in the mass spectra, and greater sequence coverage.  
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The recombinant UCH-L1 protein contains many potential sites for 
modifications as highlighted in Figure 11.  Phosphorylations are known to 
occur on the hydroxyl groups of serine, tyrosine, and threonine residues.  
Glycosyl groups are added to the side chains of asparagine, serine, and 
threonine residues. There are reports of a reciprocal relationship between 
phosphorylation and glycosylation- more specifically, O-GlcNAc modification- 
in proteins [48, 49].  With the evidence of the presence of O-GlcNAc on UCH-
L1, it is of great interest to pursue the search for phosphorylations.  
 
Figure 11: Some potential post-translational modification sites 
 
Protein phosphorylations can be quantitatively detected by the 
proteomic approaches used in this work.  One approach to mapping 
phosphorylations is to isolate UCH-L1 from the cell and treat part of the 
sample with protein phosphatases. These enzymes work to remove 
phosphate groups from amino acid residues.  Depending on the amount of 
phosphorylation, if any, the protein may be initially analyzed by two-
MQLKPMEINPEMLNKVLSRLGVAGQW RFVD 
V L G L E E E S L G S V P A P A C A L L L L F P L T A Q H E 
N F R K K Q I E E L K G Q E V S P K V Y F M K Q T I G N S C
G T I G L I H A V A N N Q D K L G F E D G S V L K Q F L S E
TEKMSPEDR AKCFEKNE AIQAAHDAVAQ EG 
QCRV DD KVN FHFIL FN NV D GHL YEL DG R MP 




dimensional gel electrophoresis to determine a difference in migration 
patterns between the phosphorylated and dephosphorylated proteins’ 
isoelectric points.  Localization of the modification is more likely to occur at 
the peptide level.  Any phosphorylations detected in pairs of peptides can be 
mapped directly to the site of modification by MS and tandem MS (MS/MS).  
Tandem MS provides more detailed sequence information by fragmenting 
molecular ions into the constituent amino acids.  In this way, modification 
sites can be located by monitoring mass shifts between the unmodified and 
modified proteins.  In the case of phosphorylation, ∆ m/z = 80 Da, for each 
phosphate group present. 
Carbohydrate groups tend to be more massive, and mass differences 
between glycosylated protein and its unmodified form can be more than 1,000 
daltons, which may be determined on high-resolution gels.  Like 
phosphorylations, glycosylations can also be enzymatically removed 
depending on the nature of the modification.  For example, peptide N-
glycosidase F will deglycosylate N-linked glycoproteins.  Chemical methods 
are used to remove O-linked glycans such as treatment with alkaline solutions 
(e.g., NaOH, Na2CO3) to promote hydrolysis via a β–elimination mechanism.  
Once the carbohydrate groups are removed, any mass differences in the 
peptide pairs can also be identified by MS/MS. 
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Chapter 5:  CONCLUSION 
Mass spectrometry is an efficient method for analyzing biomolecules in 
proteomics.  Protein characterization involves many steps, and should 
provide a thorough understanding of the protein’s structure which will 
subsequently lead to a better understanding of its function.  Characterization 
can be done through “bottom-up” proteomics where the protein is 
enzymatically cleaved into its consitutent peptides.  Bottom-up proteomics 
allows for the protein to be analyzed and reconstructed one peptide at a time.  
Because peptides are smaller and less hydrophobic than proteins, they are 
more readily analyzed by analytical techniques such as HPLC and mass 
spectrometry. 
 In this study, the recombinant form of human ubiquitin carboxy-terminal 
hydrolase L1 protein has been mapped. After being treated with two 
proteolytic enzymes, the resulting peptides are recovered and analyzed by 
mass spectrometry.  As the name suggests, peptide mass mapping allows 
identification of proteins by matching theoretical peptide mass values with 
observed values from mass spectrometry data.  Peptides from two proteolytic 
digests of UCH-L1 were used to gather structural information of UCH-L1 and 
provided 69% sequence coverage of the recombinant protein. 
 The portion of the protein sample that was not detected by these 
methods may be obtained by liquid chromatography coupled with mass 
spectrometry by providing greater peptidic separation and reducing ion 
suppression effects.  Sequence coverage may also be increased by 
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generating smaller peptides that will more likely be detected by mass 
spectrometry.  This can be done by sequential proteolysis using different 
enzymes to produce smaller sequences. 
 Searching for post-translational modifications is the final step to protein 
structure characterization.  Abnormal proteins are sometimes due to 
mutations in the gene sequence or PTMs.  Elucidation of modifications can 
lead to understanding the protein functions, or lack thereof.  Previous studies 
of UCH-L1 have found it to be modified with O-GlcNAc, a common O-linked 
glycosylation.  Other glycosylations or phosphorylations may also be a part of 
it’s structure.   
UCH-L1’s abundance in brain protein and it’s role in protein 
degradation makes it of interest to mental health researchers studying 
neurodegenerative disorders.  Furthermore, it has been implicated in 
metastasis because of expression detected outside of brain proteins.  By 
mapping the recombinant form of UCH-L1, primary structural information has 
been obtained and can be used as a model for comparison for cells in which 
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